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Abstract
The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at
good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of
ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted
Wuchereria bancrofti. Baseline LF mapping using rapid blood antigen detection tests showed mean local government area
(LGA) prevalence of 23% (range 4–62%). MDA was launched in 2000 and by 2003 had been scaled up to full geographic
coverage in all 30 LGAs in the two states; over 26 million cumulative directly observed treatments were provided by
community drug distributors over the intervention period. Reported treatment coverage for each round was $85% of the
treatment eligible population of 3.7 million, although a population-based coverage survey in 2003 showed lower coverage
(72.2%; 95% CI 65.5–79.0%). To determine impact on transmission, we monitored three LF infection parameters
(microfilaremia, antigenemia, and mosquito infection) in 10 sentinel villages (SVs) serially. The last monitoring was done in
2009, when SVs had been treated for 7–10 years. Microfilaremia in 2009 decreased by 83% from baseline (from 4.9% to
0.8%); antigenemia by 67% (from 21.6% to 7.2%); mosquito infection rate (all larval stages) by 86% (from 3.1% to 0.4%); and
mosquito infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). All changes were statistically significant. Results suggest
that LF transmission has been interrupted in 5 of the 10 SVs, based on 2009 finding of microfilaremia $1% and/or L3 stages
in mosquitoes. Four of the five SVs where transmission persists had baseline antigenemia prevalence of .25%. Longer or
additional interventions (e.g., more frequent MDA treatments, insecticidal bed nets) should be considered for ‘hot spots’
where transmission is ongoing.
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Introduction
Lymphatic Filariasis (LF) is a mosquito transmitted parasitic
infection that in Africa is caused by Wuchereria bancrofti. LF, which
has no animal reservoir, is largely rural and transmitted by
Anopheles mosquitoes in West Africa. The adult worms reside in the
human lymphatic vessels and cause lymph flow dysfunction that
can result in swelling of limbs (lymphedema, elephantiasis) and
genital organs (hydrocele), and painful recurrent febrile attacks of
acute adenolymphangitis. Microfilariae released by gravid female
W. bancrofti worms gain access to the blood stream where they
circulate at night and are available for the nocturnally feeding
mosquitoes. Microfilariae so ingested pass through three larval
molts to reach the L3 stage in about 1–2 weeks; L3 are able to
infect humans when infectious mosquitoes return to feed again.
The L3 develop to adult male and female worms, where they mate
in the human lymphatic system and females produce microfilariae,
thus completing the life cycle of the parasite [1].
LF is considered by the World Health Organization (WHO)
as one of the ‘tool ready’ neglected tropical diseases (NTDs)
[2] because LF transmission can be interrupted by safe oral
medications that markedly reduce nocturnal microfilaremia,
resulting in fewer mosquitoes being infected when they take a
blood meal [3,4,5,6,7]. Three medicines (ivermectin, diethylcar-
bamazine, and albendazole) are recommended; each has vari-
able lethal affects on the adult worms, so immediate cure of
the LF infection is not achieved with a single treatment [8].
WHO recommends annual community-wide mass drug ad-
ministration (MDA) with 150 ug/kg of ivermectin (MectizanH,
donated for this purpose by Merck) and 400 mg of albendazole
(donated by GlaxoSmithKline) for sub Saharan African LF
programs [2,8].
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the International Task Force for Disease Eradication in 1993 [9].
The current WHO endorsed strategy is based on a 1997 World
Health Assembly resolution (WHA50.29) to eliminate LF as a
public health problem in Africa by 2020 [3,4,5,6,10]. The strategy
is for MDA programs to provide treatment annually, with good
coverage, for 6 years [6,7,8]. This is based on the assumption that
the ivermectin/albendazole combination will interrupt trans-
mission in all epidemiological settings within 6 years of reaching
full geographic coverage [6,8,11], a contention that some have
challenged [12,13,14,15,16]. WHO has provided a series of
evolving guidelines for monitoring and evaluating the coverage
and impact of these programs [3,7,17,18]. In order to reach the
goal of LF elimination by 2020, African LF elimination programs
in particular need to scale up MDA to reach all targeted LF
endemic populations in the next few years [6,7].
The most populous African nation, Nigeria has an estimated
population of 150 million persons. The country is comprised of 36
states and a Federal Capital Territory that are further subdivided
into 774 local government areas (LGAs). Given wide LF endemicity
and the size of its population, Nigeria ranks third among the most
LF endemic countries in the world, after India and Indonesia [19].
Accordingly, the goal of global LF elimination cannot be reached
without success in Nigeria. Yet MDA scale up for LF to full
geographic coverage in Nigeria has lagged [6,20]. On the other
hand, Nigeria has demonstrated the capacity to undertake major
and highly successful efforts against two other NTDs, Guinea worm
disease [21] and onchocerciasis [20]. The Nigerian onchocerciasis
MDA program based on distribution of ivermectin is the largest in
theworld[22].Thus,rapidprogresscouldconceivablyalsobemade
against LF, using the MDA strategy that has been launched and
maintained so successfully for onchocerciasis.
We report on our 12 year effort to eliminate LF in Plateau and
Nasarawa states, which was the first LF elimination effort to be
launched in Nigeria. The goal of the program was to demonstrate
that annual treatment with ivermectin and albendazole on a large
scale could interrupt transmission of W. bancrofti. Ten sentinel
villages (SVs) scattered throughout the two state area were used to
measure impact of the MDA program. The two key impact
indicators for transmission interruption in these SVs) were a
microfilaremia (mf) prevalence ,1% and the absence of L3
infective larvae in the vector mosquitoes. WHO transmission
interruption criteria require both an mf prevalence ,1% in SVs
and a population based assessment of LF antigenemia in children.
We conducted such a population based assessment in Plateau and
Nasarawa states in 2008 and those results will be reported
elsewhere (King, in preparation).
Methods
Ethics Statement
The program to eliminate LF is a Federal Ministry of Health
initiative, but any individual had the right to refuse to take the
medicines offered free of charge by the program. The mapping/
rapid assessment, nocturnal blood surveys and entomological
monitoring procedures were approved by the Emory University
Institutional Review Board (protocol numbers 609–97, 153–2001,
and 435–2003) and the Plateau and Nasarawa State Ministries of
Health. Consent was obtained at three levels: the team obtained
permission from the village chief and his council by reading a
previously prepared statement with a description of the purpose of
program, and risks and benefits of the activity being performed
(mapping/rapid assessment by blood filarial antigen detection,
nocturnal blood surveys, or entomological monitoring). The
statement texts were approved by IRB and the responses to the
questions related to consent were ticked off by the team leader,
who then signed the form. A similar statement was read during
village-wide health education and mobilization sessions for
mapping and nocturnal survey activities, and a household consent
was obtained for entomological monitoring (likewise responses to
consent questions ticked off and signed by team leaders). For
individuals tested in mapping or sentinel village surveys, all
subjects provided informed consent. While written consent was
obtained when participants were literate, oral consent was
approved by the Emory IRB because literacy rates are very low
in the rural sentinel village areas. Parents/guardians gave consent
on behalf of child participants. Written or oral consent was
documented on individual laboratory/result forms filled out by
team members during mapping or sentinel village exercises.
Location of the Program
Plateau state (capital city Jos) and Nasarawa state (capital city
Lafia) are located in central Nigeria and have an estimated 4.1
million Hausa-speaking residents, 80% of whom live in agricul-
tural villages. Nasarawa state was formed from Plateau state in
1997. Both Christianity and Islam are practiced there. Plateau and
Nasarawa states were challenged by sporadic insecurity over the
years of the program related to ethnic and religious conflict, and
land ownership issues. Administratively, the two states are divided
into 30 Local Government Areas (LGAs): 17 in Plateau and 13 in
Nasarawa. Each state and each LGA has ministry of health
(MOH) structures (State ministry of health—SMOH; LGA
ministry of health—LMOH) that provide medical services through
tertiary hospitals (located in the capitals), local hospitals and
clinics. The LMOH also has community outreach activities.
History of the Integrated Program with Respect to LF
Elimination
The LF initiative in Plateau and Nasarawa states evolved as an
integrated NTD effort starting in 1997, which built upon the
annual ivermectin MDA platform for onchocerciasis (river
blindness) control launched in the early 1990s. The MOH
onchocerciasis program was initially assisted by the River
Blindness Foundation, and after 1996 by The Carter Center.
The Center works directly with and through the SMOH and
Author Summary
Lymphatic filariasis is a mosquito transmitted disease that is
best known for causing elephantiasis (grossly swollen legs
and genitals). The current strategy for halting lymphatic
filariasis in sub Saharan Africa is to establish programs that
deliver 6 or more years of annual doses of tablets in
community wide treatment programs (called mass drug
administration). The tablets are safe, and donated by Merck
& Co. and GlaxoSmithKline. We describe a mass drug
administration program in central Nigeria that has, since
2000, provided over 23 million cumulative annual treat-
ments to a population of 3.7 million persons. To assess what
should be happening generally throughout the program
area, lymphatic filariasis infection was monitored in ten
‘sentinel villages.’ In 2009, sentinel village monitoring
showed that lymphatic filariasis infection had been reduced
between 67–86% compared to levels present when the
programbegan. However, these results were not as good as
desired, and suggest that longer or increased efforts are
needed beyond 6 years if lymphatic filariasis elimination is
to be achieved.
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Ministry of Health (FMOH), which has normative oversight of
state and local activities.
The 1992 baseline onchocerciasis mapping established that 12
of the 30 LGAs required ivermectin MDA [23,24,25]. Ivermectin
treatment was launched in 1992 and full geographic coverage
achieved in all rural villages in the 12 LGAs in 1993, when about
600,000 treatments were delivered [23,24]. An integrated MDA
program was launched in 1997 with the objective of ‘piggy-
backing’ schistosomiasis control (with praziquantel MDA) and LF
elimination (with ivermectin/albendazole combination MDA)
onto the river blindness ‘platform.’ [26] Prior to adding
albendazole to the onchocerciasis MDA program, entomological
and epidemiological studies were conducted in 1998–1999. These
studies confirmed that the seven years of ivermectin monotherapy
for onchocerciasis had not halted LF transmission in the
onchocerciasis endemic LGAs [27,28].
LF Mapping
LF mapping activities were conducted in a series of surveys from
1998–2000 using various assays for the LF circulating antigen
[29]. In 1998 all villages in two LGAs (Pankshin and Akwanga)
selected to pilot the LF program were mapped using either the first
generation serum-based immunochromatographic tests [ICT card
test– AmRad North South Wales, Australia] or the Og4C3 ELISA
[TropBio, Australia]. In short, 149 villages were evaluated by
testing 4,451 male villagers $15 years of age, 22% of whom tested
positive for LF antigen, and 12.9% of whom had filarial hydrocele
on physical examination. Only 10% of village samples were LF
antigen negative. These results were reported in detail [26,30]. It
should be noted that Pankshin and Akwanga were onchocerciasis
endemic LGAs that were being treated with ivermectin when the
LF surveys took place.
In 1999–2000 mapping was launched throughout the two state
area using the WHO Operational Guidelines for Mapping of
Bancroftian Filariasis in Africa [31], in which districts (in this case
LGAs) were defined as implementation units [17]. The objective of
thesurveywasto determine the need forLFMDA(i.e., the presence
of LF transmission) with an approach biased towards finding LF
infection. In each of the 30 LGAs, villages were selected by asking
local health authorities if they knewof villages where there had been
frequent reports of clinical LF (hydrocele and/or lower extremity
lymphedema/elephantiasis) that might suggest filariasis was en-
demic. The names of those villages were written on slips of paper
and 1–4 slips for each LGA were drawn from a hat. In each sample
village, after obtaining consent from village leaders and individual
participants, LF antigen tests were preformed in 50–100 permanent
residents, all $15 years of age, with the sample equally divided
between males and females. Blood samples (100 ul measured by a
calibrated capillary tube) were obtained by finger puncture, then
transferred to the pad on the whole blood ICT test kit card (initially
produced by AmRad ICT, New South Wales, Australia; now
produced as ‘NOWH’ ICT Filariasis kits, Inverness Medical
Professional Diagnostics 2 Research Way Princeton, NJ 08540)
[32]. The test was then run per manufacturer’s instructions, with
readingtimed preciselyandpositivesbeingread when two pinklines
appeared on the card’s reagent impregnated filter paper, negatives
when one pink line appeared, and indeterminate for any other
finding. The LF village antigen prevalence was calculated by
dividing the number of positives by the total number of persons
examined. Each LGA’s prevalence was calculated as the mean of its
sample villages’ survey means. All LGAs were found to have an
antigen prevalence of .1%, which is the threshold for launching an
LGA wide MDA program (see Results).
Mass Drug Administration
In onchocerciasis co-endemic LGAs, local volunteers trained for
ivermectin distribution were present at the beginning of the LF
program. These volunteers had been trained under the guidelines
and financial support of the African Programme for Onchocer-
ciasis Control (APOC), and were known by that program as
community directed distributors (CDDs) [33,34], We retained that
designation (e.g., CDD) for the LF program to emphasize the fact
that this was an integrated delivery platform for both onchocer-
ciasis and LF . CDDs were trained or retrained annually to
distribute the ivermectin and albendazole tablets with a focus on
the need to provide health education about LF and (where
appropriate) onchocerciasis; to not confuse the ivermectin tablets
(white, small, round, unscored) with the albendazole tablets (white,
larger, oblong, scored); and to identify, report and, if necessary, to
refer persons with adverse events (AEs) occurring within 48 hours
of treatment. Ivermectin treatment was the same as that used in
onchocerciasis (150 ug/kg) and was dosed by height. A single
albendazole tablet (400 mg) was given together with the
ivermectin. Children ,90 cm height were not treated. Persons
appearing very weak or chronically ill were not treated, and
women were not treated if they reported being pregnant or
nursing a newborn under one week of age [8]. Persons with AEs
(usually headache, fever, and/or abdominal pain within 48 hours
of MDA) were treated with oral antihistamines and/or analgesics
by local health workers, who reported these results to the LMOH
supervisors. CDDs and health workers were instructed on how to
identify and refer persons with severe or unusual events occurring
post MDA to local facilities staffed by nurses or doctors.
CDDs in most instances went house to house within their areas
of responsibility to distribute the medicines; the treatment was
directly observed, and the process at the village level was usually
completed within 1–2 weeks, but state-wide activities began in
March and were not completed until December. In urban areas,
treatments were done at a central location such as a clinic,
hospital, school, church or mosque. LMOH staff members on
motorbikes provided by the program supervised treatment
activities, and villages were also independently visited in spot
checks by SMOH and/or Carter Center personnel.
A central part of the treatment process was the community
register, which was kept by each CDD. Each page in the register
was dedicated to a single household in the CDD’s area of
responsibility, and listed all residents by age and gender, starting
with the head of the family. Each household page had sufficient
space to record 7 rounds of treatment. Individual treatment was
directly observed and then immediately recorded in the register. If
an individual eligible for treatment was not present at the time of
the household visit, the CDD would return later to find and treat
that person.
Using the community register, each CDD would work with his/
her LMOH supervisor to prepare a summary report form after the
MDA was completed. At the time of the register review all unused
tablets were collected by the LMOH supervisor. In turn, working
with their SMOH supervisors, LMOH staff summarized their
LGA treatment figures monthly. These summaries were compiled
at the SMOH into a state monthly treatment report. Copies of
LGA and state monthly reports were kept at LGA, State and The
Carter Center offices. State level reports were shared with
responsible officials at the FMOH monthly.
Health Education
Health education (HE) was conducted by CDDs and LMOH
staff during mobilization activities just prior to MDA, and again
during MDA. HE aimed to provide information and understanding
LF Elimination in Two States in Nigeria
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and to encourage treatment eligible persons to take the tablets. HE
was guided and illustrated in colorful flip charts, and posters,
pamphlets, and calendars with HE messages. Prototypes were
developed and tested by Knowledge-Attitudes-Practices (KAP)
surveys conducted in 1999 in villages in the pilot LGAs of Akwanga
and Pankshin [26]. Based on the KAP results and experiences with
the initial MDAs, materials were revised and then reevaluated with
focus groups; minor modifications were made before full scale
production for the larger campaign. Onchocerciasis HE was
provided as before in coendemic LGAs at the same time as LF HE.
Scaling up
Scaling up LF MDA to full state-wide geographic coverage was
done in four phases. Phase 1 pilot (studies as described above) took
place in the two LF-onchocerciasis co-endemic LGAs of Pankshin
(Plateau state) and Akwanga (Nasarawa state), where combined
ivermectin and albendazole MDA was launched in July 2000 [26].
In 2001 (Phase 2) LF MDA expanded to the remaining 10 LF-
onchocerciasis co-endemic LGAs, and included the large towns
that had previously been untreated under the onchocerciasis
program. In 2002, Phase 3 was launched by expanding into all but
four of the non onchocerciasis (LF endemic only) LGAs where no
MDA had been previously given. Recruitment and training of an
entirely new cadre of CDDs presented new challenges to the
program that had until then been integrated into the established
onchocerciasis MDA platform. Phase 4 achieved full geographic
coverage in 2003 by launching MDA in the remaining LGAs and
the urban areas. The scale up challenge of Phase 4 was that of
assessing and treating the capital cities of Jos and Lafia for the first
time [35].
Treatment Coverage
The estimated population of the two state area is 4.1 million,
based on the 1991 National Nigerian census adjusted forward to
the year 2000, and the treatment eligible population (e.g., all
persons five years of age and above) is estimated to be 90% of the
population, or 3.7 million. That figure, deemed the Ultimate
Treatment Goal (UTG), would be the crude coverage target when
full geographic coverage was reached (e.g, when all communities
in the two state area were offered annual treatment by the
program) [36]. UTG coverage was calculated by dividing the
numbers of persons treated in a given year by the 3.7 million.
Satisfactory coverage was arbitrarily established as $85% of the
UTG.
Treatments administered compared with their respective
community denominators (based on the community CDD
registers) were determined in 2004 and 2009 across .3,600
village reports. In addition, for each of ten sentinel villages
(described in the next section) community registers were used to
determine eligible population treatment coverage annually during
the entire MDA period.
To confirm reported coverage, a cluster coverage survey was
conducted in 2003, the first year full geographic coverage of the
MDA program [17]. A 30-cluster design was used with probability
proportional to estimated community size, based on data collected
by through the CDD’s household registers. Ten households per
cluster were selected by random walk; in each sampled household
a questionnaire was administered to determine MDA compliance
by age and gender. The 2003 treatment coverage assessments
were also conducted using the same random walk technique in
nine of the ten sentinel villages (one sentinel village [Gwamlar] was
not surveyed due to insecurity).
Monitoring the Impact of the Integrated Program in
Sentinel Villages
Serologic (filarial antigen as determined by ICT test), parasi-
tologic (nocturnal blood slides stained and read for microfilare-
mia), and entomologic (mosquito dissection for LF larval infection)
were the three impact indicators monitored annually in ten
sentinel villages (SV). It should be noted that WHO guidelines
only require microfilaremia (the ‘key’ indicator) to be monitored in
SVs, so our assessment program investigated more parameters
than required. SVs were selected based on: 1) being representative
of a range of baseline antigen prevalence; 2) being representative
of all four phases of the MDA scale up; 3) being representative of
both onchocerciasis and non onchocerciasis endemic LGAs; and 4)
having village residents and leadership apparently willing to
participate in annual nocturnal blood surveys and bimonthly
mosquito collections for an indefinite period of time. The location
of the SVs is shown by stars in Figure 1, and a list of the ten SVs,
with their populations is shown in Table 1.
Nocturnal Blood Surveys
Nocturnal blood surveys were used to determine SV microfil-
aremia and antigen prevalence during the same individual blood
draw. Surveys were based on convenience samples of permanent
village residents and conducted at least 10 months after the last
MDA. Each year, one week prior to the survey, the team would
obtain permission from the village chief and his council, followed
by a village wide HE and mobilization session to explain LF and
the purpose of the nightlong survey. At the end of the meeting,
persons of all ages were asked to come on the designated night at 9
pm. On the night of the survey, an examination area was set up in
a central location and several tables and chairs were placed under
a string of light bulbs powered by a gasoline generator. A large TV
setup provided continuous video entertainment and gave the
survey scene an appealing, festive atmosphere. Guards were
present to assure the team and the residents of security during the
night. Before beginning, the team again explained the purpose of
the survey to those who had gathered. Between 10 pm–2 am,
residents aged 2 years and greater presented for examination, and
had their age and gender recorded and a finger puncture blood
specimen collected by a technician. Parents provided consent on
behalf of all child participants. Using disposable calibrated
capillary tubes, 100 ul of blood were applied to ICT card tests
that were timed and read according to manufacturer’s recom-
mendations (see above), and another 60 ul of blood were used to
prepare thick blood films. The slides were air dried and returned
to the laboratory at Carter Center headquarters in Jos for Giemsa
staining and qualitative examination for W. bancrofti microfilariae
(mf) by trained microscopists. Microfilarial counts were not
conducted; slides were read qualitatively (‘positive’ or ‘negative’).
Technicians were trained not to confuse mf of Mansonella perstans
(also prevalent in this part of Nigeria) with those of W. bancrofti. All
positive slides were confirmed by another microscopist, and 10%
of negatives were reread by another microscopist as a standard
quality control measure. Another quality control measure was to
spend extra time examining blood slides from ICT positive
persons. Results were not age adjusted and were expressed as SV
antigen prevalence (number ICT positive/number examined X
100) and SV microfilaremia prevalence (number mf slide positive/
number examined X 100).
Given the phasing of the MDA, in a given calendar year all SVs
were not in the same MDA treatment year. For example, in 2003,
the first year of full geographic coverage, SVs in Phase 4 were in
their first year of MDA, while SVs in Phase 1 were in their fourth
MDA year. In part of our analysis, we corrected for this by
LF Elimination in Two States in Nigeria
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the last year of monitoring data reported in this study, all villages
were being evaluated just prior to 2009 MDA, so that mf
prevalence represented a sampling 10 months or more after at
least six years of MDA.
‘Baseline’ mf and ICT data calculations for SVs warrant a special
comment. In the first years of SV monitoring, the Jos laboratory
experienced technical problems with Giemsa stain precipitation. As
a result, many slides were ruined and pretreatment mf prevalence
could not be established for the five SVs in Phases 1–3. In 2002 the
stain problem was solved and we were able to obtain pretreatment
mf rates for the five SVs in Phase 4 (Akwete, Azara, Babale, Dokan
Tofa, and Piapung). Since mf rates $1% wereconsidered indicative
of ongoing transmission, and because rates $1% were still found in
2002 in Phase 1–3 SVs, we choose to use the post treatment mf data
obtained in year 4 of treatment or earlier as the ‘baseline’ mf
calculation for those SVs. The exception was Gwamlar, whose first
mfdata point (also$1%)could notbe obtained until itssixthyear of
treatment(2005) duetoinsecurityinKanamLGA.Accordingly,itis
important to distinguish the term ‘mf pretreatment’ (e.g., prior to
MDA)from ‘mf baseline.’ Mf baseline is when the first SV mf values
were obtained, and such baseline data could encompass early MDA
years. We consider mf baseline as the best term to use considering
that all SVs in Phases 1 and 2 were already under ivermectin
monotherapy for onchocerciasis, so ‘pretreatment’ would be a
misnomer.
Data for the baseline antigen for five villages (Gbuwhen,
Gwamlar, Lankan, Maiganga, and Seri) were from the 1999–2000
mapping surveys where only 50–100 adults were sampled.
Subsequently larger convenience samples were tested in the
nocturnal surveys, including children as young as 2 years of age. In
LF endemic areas, adults as a rule have higher antigen prevalence
than children, so a spurious drop in prevalence between the
mapping baseline and the follow up community samples was
expected. In five villages (Akwete, Azara, Babale, Dokan Tofa,
Piapung) we combined values from the community wide pre-
treatment surveys conducted in 2002 or 2003 with the smaller
adult samples obtained in the 1999–2000 mapping surveys.
‘Baseline’ antigen results were compared with results obtained
after year 4 of MDA. However, unlike the mf analysis, antigen
data obtained between year 1 and 4 of treatment are not included
in antigen baseline calculations.
Entomology
Entomological surveys were conducted every two months in
each SV when security conditions allowed. Compounds where the
residents agreed to participate were numbered and the even
numbered compounds were serially sampled, substituting the odd
numbered compounds on occasions when residents in even
numbered compounds were not home or could not participate.
Collections in odd numbered compounds were also added when
numbers of mosquitoes were few during the dry season. Indoor
resting mosquitoes were collected in the morning using the
pyrethrum knockdown (PK) technique as previously described
[28]. The dead and dying mosquitoes that fell onto sheets draped
throughout the compound living area were collected by forceps
Figure 1. Plateau and Nasarawa States, Nigeria: Baseline LGA LF Antigen prevalence and sentinel village locations. Surveys in 70
villages sampled 6,489 adults for LF antigen in 1999 and 2000 (50–100 adult residents of each village) located in the 30 LGAs comprising Plateau and
Nasarawa states. The map is color coded based on the mean antigen results (mean of the village means): shown in red are ten LGAs having a mean
baseline antigen prevalence exceeding 25% that form a middle band stretching from southwest to northeast.
doi:10.1371/journal.pntd.0001346.g001
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www.plosntds.org 6 October 2011 | Volume 5 | Issue 10 | e1346and placed in Petri dishes having moist tissue. Dissections were
performed on the day of collection, in the village. Each mosquito
was identified as Anopheles gambiae sl, An. funestus, other Anopheles sp,
Culex sp or ‘other’, and separated into head, thorax and abdomen
on a glass slide under a binocular dissecting microscope. Each of
these was teased open in a drop of normal saline. The slide
preparation was then passed to 1006under a regular microscope
where a trained microscopist noted the presence or absence of
larval stages (L1–3). Similar to the blood slides, larval stages were
recorded qualitatively for any larval stage (positive/negative), and
the presence or absence of L3 (positive/negative); numbers of
larvae in each stage were not quantified. If more mosquitoes were
collected than could be dissected in a day, all Anophelines sp
mosquitoes were placed in capped tubes with desiccant, labeled,
and stored for future molecular testing. Data on each dissected
mosquito were entered into a log book and later entered into an
Excel file. In the analysis, infected mosquitoes were defined as
having any larval stage (L1, L2, or L3). Infectious mosquitoes were
defined as those containing L3. Microfilariae found in abdominal
examination of blood fed mosquitoes were not considered in the
analysis since we were not interested in a xenodiagnostic picture of
the inhabitants of the sampled compound where the mosquitoes
were collected [37]. Instead, our analysis focused on only W.
bancrofti larval stages so as to provide an index of community-wide
parasite transmission [28]. SV results from the six outings of the
year were summed; at least 100 mosquitoes needed to be dissected
in a year for that SV result (of that year) to be included in the
analysis. ‘Baseline’ mosquito infection rates were aggregate results
from ‘pretreatment’ and the first two years of ivermectin/
albendazole MDA. The finding of one or more mosquitoes
containing infectious larvae (L3) was considered to be indicative of
active LF transmission in that SV during the year.
Statistical Testing
Results of coverage and SV surveys were analyzed in Epi Info 6
(CDC, Atlanta, USA), SAS (SAS institute, Cary, NC), Stata 8.2
(Stata Corporation, College Station, TX) and SUDAAN (Re-
search Triangle Institute, Research Triangle Park, NC). The 2003
treatment coverage survey results and summary SV MDA
treatment year aggregate results were expressed with exact
binomial 95% confidence intervals. Significance of trends between
SV MDA year aggregate values for microfilaremia prevalence,
antigen prevalence, and mosquito infection was determined using
a Mantel chi-square for trend analysis. Differences between
baseline and 2009 microfilaremia prevalence, antigen prevalence,
and mosquito infection were compared as categorical data using
Pearson chi-square (two tailed) test considering a p-value ,0.05 as
significant and ,0.01 as highly significant. Given the importance
of the sixth MDA year in WHO LF elimination policy, statistical
testing comparing indices in the sixth MDA year with baseline was
also undertaken.
Results
LF Mapping
Mapping exercises (Figure 1) to determine LF circulating
antigen prevalence were conducted in 1999–2000 in 70 villages in
the 30 LGAs. Two villages were sampled from each LGA, with the
exception of Toto, Akwanga, Pankshin and Wase (4 villages each);
Karu, Jos East, and Shendam (3 villages each); and Keffi and Jos
North (1 village each). A total of 6,489 adults were tested, of whom
1,305 (20%) were positive. The mean LGA prevalence (based on
the mean of the village means) for the two state area was 23%
(range 4–62%). The two states were quite similar, with the
Nasarawa mean village prevalence being 21% (range 4–54%) and
the Plateau village prevalence mean being 24% (range 4–62%).
Figure 1 shows the LGA antigen prevalence stratified by
endemicity. The entire two state area was targeted for MDA with
ivermectin and albendazole because mapping showed that each
LGA implementation unit sampled had an antigen prevalence in
adults of .1%. The 30 LGAs were listed in order of descending
prevalence and divided into terciles. The upper tercile (10 LGAs)
was noted to have an antigen prevalence .25%: these were
Akwanga, Doma, Lafia, Obi and Wamba in Nasarawa state, and
Kanke, Mangu, Qua’an Pan and Pankshin in Plateau. The spatial
distribution of the upper tercile formed an interesting middle band
extending from southwest to northeast.
Mass Drug Administration
Figure 2 shows the numbers of treatments provided by the
onchocerciasis MDA program (launched in 1992), followed by
arrows indicating the phasing in of the LF program (launched in
2000). Expansion into non onchocerciasis endemic areas began in
Phase 3, and the LF program reached its full geographic coverage
in Phase 4 (that included the major urban areas of Jos and Lafia).
Given the magnitude of the scale up required to reach all LF
endemic areas, treatments had to be increased 4.6 fold between
Phase 2 (when 675,701 treatments were provided) and Phase 4
(when 3,112,379 treatments were provided). Accomplishing this
scale up required a three fold increase in CDDs, from 2,424 in the
year 2000 to 6,899 by 2003. To maximize coverage and minimize
workload, the program continued to recruit and train CDDs
annually, training 10,011 in 2009. At that point, each CDD was
responsible for treating an average of 347 persons.
Treatment was provided in 8 LGAs for seven years (2003–2009,
Figure 2) after full geographic coverage was obtained. However,
two LGAs from Phase 1 pilot (Pankshin and Akwanga) were
treated for ten years, 10 LGAs from Phase 2 for nine years, and
10 LGAs from Phase 3 for eight years. Note that the Phase 1
and 2 LGAs treated for the longest periods (9–10 years) with
combination ivermectin/albendazole also had (from 1992–1999)
an additional 8–9 years of ivermectin MDA monotherapy for
onchocerciasis. A cumulative total of 26,352,060 combination
ivermectin and albendazole treatments were administered in
Plateau and Nasarawa states over the ten year LF elimination
effort (2000–2009).
Reported Treatment Coverage
Scaling up to full geographic coverage was complete in 2003,
four years after launching the program; 85% coverage of UTG
was first reached in 2003, and then exceeded 87% for the next six
years. Annual reported coverage in each of the ten SVs over this
period (Table 1) showed a mean treatment coverage of 91% (range
50–100%). However, civil unrest prevented treatment in the
Babale urban sentinel site in Jos East in 2009. Figure 3 shows
reported village level treatment coverage, by coverage ranges, for
the years 2004 and 2009. Forty-nine percent of 3,677 villages
reported $85% coverage of the eligible population in 2006, while
73% of 3,638 villages reached that goal in 2009.
Surveyed Treatment Coverage
The 2003 cluster coverage survey provided treatment figures for
4,524 treatment eligible persons (defined as age $5 years) drawn
from a sample frame that included all 30 LGAs. Coverage was
72.2% (95% CI 65.5–79.0), and did not vary significantly between
states. The 2003 urban coverage (n=1,322) was 61.9% (CI 56.6–
67). Surveyed coverage in the sentinel villages in 2003 was
82% (Table 1), which was significantly higher than that of entire
LF Elimination in Two States in Nigeria
www.plosntds.org 7 October 2011 | Volume 5 | Issue 10 | e1346two-state area, but lower than the 90% reported in SV treatment
registers for that year.
Surveillance for Adverse Events
Rates of adverse event reporting during the scale up period
(2001–2003) ranged from 0.41–1.16%, and were lower (0.10–
0.24%) in the years thereafter. This was as expected, since the
most reactions are likely during the first rounds of therapy, when
highest mf density carriers are present in the population. Events
reported were also as expected, being primarily headache, fever
and abdominal pain; there were no reports of scrotal pain or
swelling noted in some LF areas treated with diethylcarbamazine
(DEC)/albendazole MDA [38]. No life threatening reactions, or
reactions requiring hospitalization, were reported during the ten
year period.
Monitoring the Impact in SVs
Nocturnal microfilaremia. Achieving a nocturnal micro-
filaremia (mf) prevalence of ,1% is the key WHO indicator of
transmission for SVs. Mean SV mf prevalence (Table 2) dropped
from a baseline of 4.9% to 0.9% in 2009 (p,0.01). In 2009
evaluations (10 months after the 2008 treatment), 7 of 9 SVs
monitored had an mf prevalence under the 1% threshold. The two
SVs with mf prevalence $1% were Gwamlar (4.9% after 8 years
of MDA) and Piapung (2.1% after 7 years of MDA). However,
recent annual fluctuations around that important threshold
occurred for Seri, Maiganga, and Lankan. Mean mf prevalence
adjusted by MDA year (Figure 4) decreased from 4.9% at baseline
to 0% in year 10, but hovered above the critical 1% mark for all
other years; after the sixth MDA the mean mf prevalence was
1.8%. The analysis for trend was significant (p=0.035).
LF antigen. The mean SV baseline antigen level (Table 3) of
21.6% dropped quickly to 10–15% due in large part to age
sampling differences. Five SVs had 2009 antigen prevalence over
5%, with Gwamlar having a very remarkable 27.3% despite 8
years of MDA. When adjusted by MDA treatment year (Figure 5),
a plateau is observed during years 5–8, resulting in an inability to
demonstrate a significant trend over the period (p=0.06). Testing
between individual years show antigen levels after year 6 of MDA
were significantly lower than baseline (p,0.01), even though year
6 antigen levels were still more than 50% of the baseline value
(15.5% versus 21.6%).
Entomology. Anopheline mosquitoes made up 96% of PK
captures: 78% of captures were Anopheles gambiae s.l. and 18% An.
funestus; Culex species were 3%. Only Anopheles sp mosquitoes were
found infected with larvae of W. bancrofti. Table 4 shows baseline
and annual infection rates, which were lowest in 2009 (0.4% of
4,398 dissections) and significantly reduced compared to baseline
(p,0.01). Mosquito infection rates adjusted by treatment year
(Figure 6) show a similar plateau to antigen levels during years 3–
6, with an overall decrease from a 3.1% baseline to 0.1% in year
10. Infections were 1.6% in the sixth MDA year (significantly
lower than baseline, p,0.01) and an overall highly significant
trend analysis.
Phase 4 SVs. Phase 4 SVs were instructive because they were
not pretreated with ivermectin monotherapy for onchocerciasis
and they received LF MDA for the shortest period of time (six
years). Piapung and Dokan Tofa were the most interesting because
they had the highest pretreatment antigen and mf data of the
Phase 4 SVs: Piapung had a baseline (pretreatment) mf prevalence
of 9.9%, and antigen level of 31.8%; Dokan Tofa a baseline
(pretreatment) mf prevalence of 5.0%, and antigen of 23.5%. Both
Figure 2. Scaling up onchocerciasis and lymphatic filariasis treatments: 1992–2009. Light bars show ivermectin monotherapy for
onchocerciasis MDA provided in rural villages in 12 LGAs deemed onchocerciasis endemic in 1992. Dark bars show LF treatment with ivermectin and
albendazole combination therapy. Arrows indicate LF scale-up phases. Phase 1: pilot studies completed in two onchocerciasis endemic LGAs
(Pankshin in Plateau state and Akwanga in Nasarawa state). Phase 2: LF MDA expanded to the remaining 10 onchocerciasis endemic LGAs, to now
include large towns in those LGAs that had previously been untreated under the onchocerciasis program. MDA in Phases 1 and 2 was for both
onchocerciasis control and LF elimination. Phase 3: LF MDA expanded to all but four of the non-onchocerciasis endemic LGAs. Phase 4: LF MDA
reached full geographic coverage (all 30 LGAs) and the capital cities of Jos (Plateau) and Lafia (Nasarawa). MDA added in Phases 3 and 4 were only for
the purpose of LF elimination.
doi:10.1371/journal.pntd.0001346.g002
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Baseline 2004 2005 2006 2007 2008 2009
Sentinel
Village LGA
Years
of Tx % pos n % pos n % pos n % pos n % pos n % pos n % pos n
Akwete*** Awe 7 0.5% 424 NA NA NA NA NA NA 0.0% 81 0.0% 45 0.0% 168
Azara*** Awe 7 0.2% 402 NA NA NA NA NA NA 0.0% 20 0.0% 61 0.0% 109
Babale*** Jos North 7 0.4% 261 NA NA NA NA NA NA 0.0% 96 0.0% 68 NA NA
Dokan Tofa*** Shendan 7 5.0% 419 NA NA NA NA NA NA 1.3% 151 0.0% 158 0.4% 223
Gbuwhen6 Akwanga 10 3.7% 508 1.8% 446 0.3% 286 0.5% 183 0.0% 196 0.0% 127 0.0% 175
Gwamlar** Kanam 8 6.7% 494 NA NA NA NA 12.1% 240 1.6% 128 5.0% 100 4.9% 143
Lankan6 Pankshin 10 3.3% 274 7.4% 365 4.5% 243 2.5% 81 1.7% 117 4.0% 173 0.0% 201
Maiganga* Wamba 9 4.7% 486 NA NA 3.0% 169 5.6% 126 0.6% 158 1.8% 109 0.7% 152
Piapung*** Mikang 7 9.9% 403 NA NA NA NA NA NA 9.6% 187 NA NA 2.1% 291
Seri* Kanke 9 10.6% 527 NA NA 1.6% 321 1.3% 157 0.8% 133 2.7% 110 0.0% 258
TOTAL 4.9% 4,198 4.3% 811 2.2% 1,019 5.2% 787 2.1% 1,267 1.8% 951 0.9% 1,720
Nocturnal microfilaremia as determined by 60 ul thick smear. The total n value in the table is also reflected in the related graph (Figure 4). Baseline data point is
explained in Figure 4 legend. NA=not applicable or not available.
uStarted treatment in 2000.
*Started treatment in 2001.
**Started treatment in 2002.
***Started treatment in 2003.
doi:10.1371/journal.pntd.0001346.t002
Figure 3. Reported village treatment coverage (eligible population): 2004 and 2009. This x axis shows reported village level treatment
coverage ranges based on community CDD registers, and the y axis shows the percent of villages that reported coverages falling into that treatment
coverage range for the years 2004 and 2009. Forty-nine percent of 3677 villages reported over 85% coverage of the eligible population in 2006, while
73% of 3638 villages reached that goal in 2009.
doi:10.1371/journal.pntd.0001346.g003
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Baseline 2004 2005 2007 2008 2009
Sentinel Village LGA Years of Tx % pos n % pos n % pos n % pos n % pos n % pos n
Akwete*** Awe 7 13.5% 474 NA NA NA NA 5.8% 191 6.6% 45 2.4% 168
Azara*** Awe 7 9.3% 452 NA NA NA NA 2.2% 185 4.9% 61 0.9% 109
Babale*** Jos North 7 6.4% 311 NA NA NA NA 1.5% 324 1.5% 68 unrest NA
Dokan Tofa*** Shendan 7 23.5% 469 NA NA NA NA 14.4% 277 8.7% 158 3.0% 223
Gbuwhen6 Akwanga 10 46.7% 30 5.2% 446 4.5% 178 6.4% 282 0.0% 127 0.6% 175
Gwamlar** Kanam 8 58.0% 50 NA NA NA NA 31.5% 270 17.0% 100 27.3% 143
Lankan6 Pankshin 10 47.0% 100 23.6% 365 19.0% 200 20.6% 253 9.6% 178 7.0% 201
Maiganga* Wamba 9 54.0% 50 NA NA 20.6% 165 19.2% 234 1.8% 109 7.9% 152
Piapung*** Mikang 7 31.8% 453 NA NA NA NA 19.6% 312 14.5% 62 7.6% 291
Seri* Kanke 9 62.0% 50 NA NA 13.0% 150 22.6% 385 8.2% 110 10.5% 258
TOTAL 21.6% 2,439 13.4% 811 14.4% 693 15.0% 2,713 7.4% 1,018 7.4% 1,720
Filarial antigenemia as determined by ICT test. Baseline data point is explained in Figure 5 legend. The total n value in the table is also reflected in the related graph
(Figure 5). NA=not applicable or not available.
uStarted treatment in 2000.
*Started treatment in 2001.
**Started treatment in 2002.
***Started treatment in 2003.
doi:10.1371/journal.pntd.0001346.t003
Figure 4. Mean sentinel village microfilaremia prevalence by MDA treatment year (n=10,753). Nocturnal microfilaremia as determined
by 60 ul thick smear. SV results across all four MDA phases have been adjusted to MDA treatment year for comparability. No pretreatment data are
available for Gbuwhen, Gwamlar, Lankan, Maiganga and Seri, so earliest available mf data point was used as the baseline figure. Bars show 95%
confidence intervals. Chi square for trend for all years was significant (p=0.035), but was not significant using an analysis between baseline and MDA
year 6 (p=0.187). In addition, the key threshold of ,1% microfilaremia was not attained by MDA year 6.
doi:10.1371/journal.pntd.0001346.g004
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coverage of $85% (Table 1). Ten months after the sixth round of
MDA, the change from baseline mf (Table 2) and antigen (Table 3)
levels was statistically significant for both SVs (p,0.01). However,
Piapung did not reach the ,1% mf threshold, with a 2009 mf
prevalence of 2.1% compared to Dokan Tofa (mf prevalence
0.4%). Age specific mf and antigen prevalence for these two SVs at
baseline and 10 months after the Year 6 MDA treatment round
are shown in Figure 7. Both villages show remarkable changes in
both parameters in most age groups. In Piapung, which began
with antigen levels representing the upper tercile (.25%), these
changes are less dramatic. Both villages, however, showed a
concerning number of 6–10 year old children with positive antigen
tests, which could suggest ongoing transmission in both villages
(Antigen positive children 5 years and under was not demonstrated
at either baseline or follow-up). In entomological evaluations, an
L3 (infective) mosquito was captured in Dokan Tofa in 2009.
Overall assessment of transmission based on SV
studies. Table 5 is a summary table showing baseline and
final (2009) measurements of mf, antigen, and mosquito infection
and infectivity rates in the SVs. Average mf in the ten SVs
decreased by 83%, from 4.9% to 0.8%, while the decrease of
antigenemia was less marked at 67% (from 21.6% to 7.2%).
Summary entomological data showed that the overall mosquito
infection rate decreased by 86% (from 3.1% to 0.4%) and
mosquito infectivity rate decreased by 76% (from 1.3% to 0.3%).
All findings were highly statistically significant (p,0.01), as were
many, but not all, individual SV decreases between baseline and
2009.
The final column in Table 5 summarizes these findings into our
conclusions as to whether transmission was interrupted based on 1)
mf prevalence being ,1% and/or 2) absence of L3 in mosquito
dissections. We did not make judgments based on community-
wide LF antigen results since most experts restrict assessments of
antigen to younger age groups [7,18,39,40]. If only the WHO SV
standard of mf,1% were considered, then transmission interrup-
tion would have been judged to have occurred in 8 SVs, with the
failures being Gwamlar (2009 mf prevalence of 4.9%) and Piapung
(2009 mf=2.1%). Using our entomological criterion (evidence of
circulating L3 in vector mosquitoes), 4 of the 10 SVs (Gwamlar
again, Dokan Tofa, Lankan, and Seri) had evidence of
transmission. Taken together, therefore, we concluded that LF
transmission had been interrupted in only 5 SVs. In this regard,
considering initial force of transmission and its relationship to
breaking transmission, it is useful to note that the successful SVs
(with interrupted transmission) had baseline values that represent-
ed an average of 1.9% mf, 0.7% mosquito infection and 0.25%
mosquito infectivity, compared to 7.1%, 7.9% and 3.3%
respectively for baseline in SVs with ongoing transmission in 2009.
Six of the SVs had initial antigen levels that were .25% (the
upper tercile cutoff in the mapping results. Four of the SVs were
below this cutoff, with baseline antigen levels ranging from 6.4%
to 23.5%. Of the six SVs with endemicity representing the upper
tercile, four showed evidence of ongoing transmission in 2009. In
Figure 5. Mean sentinel village antigen prevalence by MDA treatment year (n=9,394). Filarial antigenemia as determined by ICT testing.
SV results across all four MDA phases have been adjusted to MDA treatment year for comparability. Data for the baseline antigen for five villages
(Gbuwhen, Gwamlar, Lankan, Maiganga, and Seri) were from 1999–2000 mapping surveys. Baseline for the remaining villages (Akwete, Anzara,
Babale, Dokan Tofa, Piapung) combined values from the community wide nocturnal pre-treatment surveys conducted in 2003 with pre-treatment
data from the 1999–2000 mapping surveys. Chi square for trend not significant (p=0.06 for all MDA years and p=0.271 for baseline through MDA
year 6). Bars show 95% confidence intervals.
doi:10.1371/journal.pntd.0001346.g005
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www.plosntds.org 12 October 2011 | Volume 5 | Issue 10 | e1346contrast, only one of the four lower endemicity SVs in 2009 failed
to interrupt transmission (due to a single infectious mosquito
captured in Dokan Tofa). However, it should be noted that the
other 3 SV (Akwete, Azara, and Babale), would have passed WHO
SV transmission interruption criterion at baseline, before MDA
was even launched (despite these SVs having baseline MDA
antigen prevalences above the 1% launch MDA threshold that
ranged from 6.4–13.5%). None of these SVs had been ‘pretreated’
with ivermectin for onchocerciasis.
Discussion
We describe a large program scale up experience using annual
combination ivermectin/albendazole mass drug administration
(MDA) to interrupt anopheline transmitted W. bancrofti in two
Nigerian states. To measure success, we serially monitored three
infection parameters (microfilaremia, antigenemia, and mosquito
infection) in 10 sentinel villages (SVs) scattered throughout
the two state area. During the ten year SV monitoring period
.10,000 nocturnal blood smears were read, .9,000 ICT tests
performed, and .44,000 mosquitoes dissected. We found that
the MDA program significantly reduced all overall infection
parameters in 2009 compared to baseline. However, based on
presence of microfilaremia $1% and/or the finding of L3 stages
in mosquitoes, we believe that LF transmission continued
uninterrupted in half of the SVs after six or more years of
MDA. However, use of the WHO SV standard based on mf alone,
80% of the SVs were successful. In both cases, our findings
are consistent with other reports noting that extended MDA
intervention beyond six years may be required in some
instances [13].
The success of the MDA strategy for LF rests on achieving and
sustaining very high treatment coverage [7,12,13,41]. Reported
treatment coverage in Plateau and Nasarawa states was $85% of
the 3.7 million treatment eligible persons aged $5 years (.77% of
the total population of 4.1 million). However, population-based
cluster surveys in 2003 (the first year of full geographic coverage)
showed eligible population coverage of 72.2% (95% CI 65.5–
79.0); below the 85% we sought. Discrepancies between reported
and surveyed coverage have been previously noted by WHO LF
technical committees [11]. We also surveyed the SVs in 2003, and
found 82% of eligible persons reported taking the tablets, a figure
below the reported SV coverage figures (90%) and above the 79%
(upper 95% CI) determined by the state-wide population based
survey. Thus, the impact results from the SVs represent the best
case scenario for the two state area, but ambiguous (within the SVs
themselves) with respect to the 85% treatment goal. An analysis of
reported village coverage figures based on treatment registers kept
by CDDs for 2009 showed that a quarter of villages failed to
achieve the desired coverage. Program managers need to conduct
analyses such as these to detect the subset of communities that
require action to improve coverage [13,15]. Further operations
research in this area is needed.
The most important indicator in our SV monitoring activities
was nocturnal microfilaremia. The WHO guidelines suggest SV
monitoring of mf be conducted serially in each implementation
unit during the MDA treatment period until a prevalence of ,1%
is reached. At that threshold, population based antigen surveys
Figure 6. Mean mosquito infection (all larval stages) by MDA treatment year in 10 sentinel villages (n=44,668). Dissections from
bimonthly intradomiciliary pyrethrum knockdown collected mosquitos for all larval stages (L1–3) combined across all SVs and adjusted to MDA
treatment year for comparability. Baseline mosquito infection rates are the aggregate values from pretreatment and the first two years of treatment;
no baseline data were available for Babale SV. Chi square for trend for all years was highly significant (p=0.008), but the trend analysis was not
significant using data between baseline and MDA year 6 (p=0.131). Bars show 95% confidence intervals.
doi:10.1371/journal.pntd.0001346.g006
LF Elimination in Two States in Nigeria
www.plosntds.org 13 October 2011 | Volume 5 | Issue 10 | e1346Figure 7. Age-specific prevalence for mf or LF antigen in Dokan Tofa and Piapung sentinel villages. Panel A: Dokan Tofa pretreatment
prevalence byagegroup(n=418). PanelB: Piapung pretreatment prevalencebyagegroup(n=400). PanelC:DokanTofa prevalenceby age groupafter
6 rounds ofMDA(n=223). PanelD: Piapung prevalence by agegroupafter 6 rounds of MDA (n=280).Boxes show numbers sampledin each agegroup.
Pretreatment sample for mf is different from Table 2 because ages were not available on all persons tested. Pretreatment sample for antigen for these
SVs are different than baseline figure shown in Table 3 because 1999/2000 mapping data were added to baseline calculation in Table 3 (see Methods).
doi:10.1371/journal.pntd.0001346.g007
Table 5. Baseline and 2009 microfilaria, antigenemia and mosquito infection/infectivity in 10 SVs, and 2009 transmission status.
Mf Antigenemia Mosquito Infection
Mosquito Infectivity
(L3)
2009
Transmission
Sentinel
Village LGA
Years
of Tx Base 2009 % Base 2009 % Base 2009 % Base 2009 %
Akwete Awe 7 0.5% 0.0% 100% 13.5% 2.4%* 82% 0.1% 0.0% 100% 0.0% 0.0% N/A Interrupted
Azara Awe 7 0.2% 0.0% 100% 9.3% 0.9%* 90% 0.0% 0.0% N/A 0.0% 0.0% N/A Interrupted
Babale Jos North 7 0.4% 0.0% 100% 6.4% 1.5% 77% NA 0.0% N/A NA 0.0% N/A Interrupted
Dokan Tofa Shendan 7 5.0% 0.4%* 91% 23.5% 3.0%* 87% 2.4% 0.1%* 94% 1.0% 0.1%** 86% Ongoing
Gbuwhen Akwanga 10 3.7% 0.0%* 100% 46.7% 0.6%* 99% 0.6% 0.0% 100% 0.1% 0.0% 100% Interrupted
Gwamlar Kanam 8 6.7% 4.9% 27% 58.0% 27.3%* 53% 19.0% 2.3%* 88% 8.2% 0.9%* 90% Ongoing
Lankan Pankshin 10 3.3% 0.0%* 100% 47.0% 7.0%* 85% 5.9% 0.3%* 95% 2.3% 0.3%** 87% Ongoing
Maiganga Wamba 9 4.7% 0.7%** 86% 54.0% 7.9%* 85% 2.1% 0.3%** 87% 0.9% 0.0%** 100% Interrupted
Piapung Mikang 7 9.9% 2.1%* 79% 31.8% 7.6%* 76% 5.7% 0.2%* 96% 3.0% 0.0%* 100% Ongoing
Seri Kanke 9 10.6% 0.0%* 100% 62.0% 10.5%* 83% 6.7% 1.0%* 84% 2.0% 0.9% 57% Ongoing
TOTAL 4.9% 0.8%* 83% 21.6% 7.2%* 67% 3.1% 0.4%* 86% 1.3% 0.3%* 76%
% columns indicate percent decrease from baseline. 2009 Transmission status column (far right) indicates ‘interrupted’ only when Mf,1% and Mosquito Infectivity
(L3)=0. Babale final impact data points are from 2008 due to unrest in 2009. Azara mosquito infection final impact data point is from 2007 due to small sample sizes
(,100) in 2008 and 2009.
*p,.01 compared to baseline.
**p,.05 compared to baseline.
doi:10.1371/journal.pntd.0001346.t005
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TAS) must be conducted to enable a full determination of
transmission status and a ‘stop treatment’ decision for the
implementation unit [7,13,18]. In Plateau and Nasarawa states,
the costs and logistical challenges of monitoring 30 SVs (one in
each LGA) were beyond the program’s capacity [11]. Thus, we
monitored only 10 SVs, but as a result we are unable to make
individual LGA decisions based on SV data. The 83% decrease in
mf compared to baseline is consistent with other reports [42].
Encouraged by these findings, and by the fact that 80% of SVs
achieved the ,1% goal, we elected to conduct a major ‘TAS-like’
population-based cluster survey to determine antigen prevalence
for each LGA to decide where MDA could be stopped, and where
MDA needed to continue. These results will be reported separately
(King et al. in preparation).
The serial ICT testing in this study, while not required by
WHO guidelines, provides insight into antigen decay in MDA
programs based on ivermectin and albendazole. As expected, SV
antigenemia decreased less dramatically than mf. The 2009
antigen prevalence remained above the 1% threshold used in 2000
to determine if MDA should be launched (8 of the ten SVs were
above 1% antigenemia in 2009). It is likely that the drug
combinations using ivermectin result in slower antigen decay than
in MDA programs using DEC, which is more effective against the
adult W. bancrofi worms [43]. Persistent antigenemia may not
necessarily be an indicator of reproductively viable adult W.
bancrofti worms that pose a threat of reestablishing transmission
after MDA is withdrawn [8]. Therefore the importance of
community wide antigen prevalence after many years of MDA is
unclear, and not an indicator of treatment failure. Unlike mf,
antigen decay should not fluctuate with the MDA treatment cycle,
so antigen results are a reflection of the MDA year in which the
test was performed. Therefore, our analysis suggests that antigen
levels will remain .1% after ten years of MDA (Figure 5).
The SV entomology studies are relatively unique to the Plateau
Nasarawa experience; such work is not a part of WHO guidelines
[7,18,37]. Our dissections left us with a bleaker impression of
impact than if we had used microfilaremia as the sole transmission
criterion. Mosquito infectivity rates (L3 stages) provided immedi-
ate (‘real time’) evidence for community LF transmission activity
[44,45]. Based on bimonthly monitoring of mosquito infection in
selected compounds, the average 2009 infection rate decreased
significantly compared to baseline by 86% (from 3.1% to 0.4%);
and infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). Using
a finding of a single L3 as evidence of active transmission, we
reclassified 3 SVs from ‘transmission interrupted’ (based on having
microfilaremia ,1%) to ‘transmission ongoing’ (Table 5). Models
suggest that some residual L3 may circulate even after the
transmission breakpoint has been reached (e.g., when W. bancrofti
population is in irreversible decline) [12,41], so our use of this
stringent entomologic criterion divorced from entomological
inoculation rates or transmission potential calculations could be
challenged [44,45,46].
The MDA program took four years to scale up to full geographic
coverage. As a result, by 2009, different LGAs had different MDA
exposure histories. To better understand the annual impact of the
treatment program we adjusted for these LGA differences by
combining SV data by their MDA treatment year (Figures 4, 5, and
6). The MDA year analysis suggests that, had full geographic
coverage beenobtained immediately in all LGAs, ten years of MDA
would be required to achieve mf ,1% in all SVs; even at ten years
4% antigenemia and low grade mosquito infection (including L3—
Table 5: Pankshin) might still be found. WHOtechnical committees
continue to grapple with this problem [11,13].
This analysis is complicated by the fact that the LF program was
launched within onchocerciasis LGAs by first piggybacking onto
the onchocerciasis MDA logistics. While this made programmatic
sense, epidemiologically it meant that the LGAs likely to need the
least MDA treatment (having had six or more years of ivermectin
monotherapy for onchocerciasis) were the same ones to benefit
from the longest treatment with the ivermectin and albendazole
combination. The ivermectin ‘naı ¨ve’ LGAs of Phases 3 and 4 had
considerably shorter drug experiences, and the SVs in these LGAs
were the most instructive in terms of the WHO six year MDA
treatment policy. Most important among these were Dokan Tofa
and Piapung because they had the highest baseline mf and antigen
prevalences of Phases 3–4 SVs. By 2009, the MDA program had
significantly decreased mf, antigen and mosquito infection rates in
Dokan Tofa and Piapung (Table 5), yet both SVs failed to meet
our criteria for interrupted transmission: Piapung had microfila-
remia above 1% , and Dokan Tofa (while mf were ,1%) was
found to have an infective mosquito. Piapung, the only one of the
two that failed the WHO SV criteria (mf,1%), began treatment in
the mapping upper tercile antigen category of .25%.
One SV (Gwamlar) was an MDA treatment failure: after 8 years
of dual MDA, and earlier ivermectin monotherapy for onchocer-
ciasis, 2009 monitoring showed microfilaremia of 4.9%, statisti-
cally unchanged from the baseline of 6.7%. This may have been
because of frequent insecurity in the Kanam LGA, where
Gwamlar is located. It was also only in Gwamlar that we accepted
a ‘baseline’ mf data point in the sixth year of treatment (2005).
There could have been a considerable drop in mf from an earlier
(unmeasured) point in time. However, antigen prevalence in 2009
was highest of all SVs (27.3%) and mosquito infection rates .2%
(with L3 found). Gwamlar’s reported coverage figures were
acceptable (interval mean of 86% – Table 1), but it was the one
SV where the 2003 coverage survey was not conducted, due to
insecurity. A detailed reassessment and increased interventional
effort are needed there. Similar SV MDA treatment failures have
been reported in Burkina Faso [13] and Ghana [42].
Each of the 30 LGAs was considered as a separate
‘implementation unit,’ to be ultimately judged separately with
respect to LF transmission status and the decision to continue or
halt the MDA intervention. Based on the initial mapping results,
the upper tercile of ten LGAs showed an antigen prevalence of
.25%. We assumed that transmission would be most difficult to
break in those LGAs. We can test that hypothesis by comparing
SV success at interrupting transmission by whether they had
antigen levels .25% at baseline. We found that 4 of the 6 SVs
having baseline antigen levels of .25% failed to interrupt
transmission, compared to 1 of 4 SVs with baseline antigen
#25%. Gwamlar’s LGA, Kanam, had the second highest baseline
antigen results in the mapping survey (44%), superseded only by
Kanke LGA (baseline antigen 51%), whose SV (Seri) achieved
,1% mf but not the absent L3 threshold. These observations
support the idea that LGAs with greater endemicity (in this case
those exceeding 25% antigen prevalence shown in red in the map
in Figure 1) are likely to be the primary areas of risk of MDA
failure in Plateau and Nasarawa states beyond 2009. It also
appears to support the principle that an eradication or elimination
program should seek to intervene as early as possible in the highest
endemic areas, since they will require the longest time to interrupt
transmission.
A change in activities to meet the challenges of the ‘end-game’
for this LF MDA program now needs to be considered [11]. Our
data suggest that in some LGAs the MDA program could be
halted, while in others six or more years of annual MDA alone
has failed to interrupt transmission. Additional interventions are
LF Elimination in Two States in Nigeria
www.plosntds.org 15 October 2011 | Volume 5 | Issue 10 | e1346needed there, such as twice per year treatment, [47,48] and/or
insecticide treated bednets [12,46,49,50]. The 2010/2011 distri-
bution of long lasting insecticidal nets (LLIN) throughout Plateau
and Nasarawa states by the national malaria program (with of goal
of providing 2 LLIN per household) is a welcome addition to LF
interventions.
There were several weaknesses to the monitoring program.
First, SV coverage figures fall into the highest range of coverage
values, and so SV impact results are not likely to be representative
of all villages in the two-state area. Second, at least one additional
coverage survey after 2003 would have been useful to compare
with reported coverage results, especially given the increase in
CDD numbers that occurred after that year. Third, building an
experienced and trained monitoring team took time, and we were
hampered by laboratory problems with Giemsa staining of blood
slides (for the all-important mf monitoring) in the first years of the
program, resulting in the loss of hundreds of baseline mf slides.
Fourth, SV residents became tired of the annual nocturnal blood
surveys and participation rates dropped over the course of the
monitoring process. An example of the change in the represen-
tativeness of the SV samples can be seen in the 60% drop in
participation rates between 2003 and 2009 nocturnal surveys in
Dokan Tofa and Piapung SVs (Figure 7). Future nocturnal SV
evaluations should be done less frequently, and not at all in the first
3 years of the MDA program. SV work should be staggered so that
communities do not become fatigued, but evaluation teams do not
lose their hard-earned field and laboratory skills. When the
Nigerian LF program goes to scale, the most experienced technical
teams from mature LF program states should move from state to
state to provide training and oversight in the monitoring activities.
Fifth, we did not count microfilaria on blood slides, nor did we
record numbers of L1, L2 and L3 larvae found in positive
mosquitoes. This prevented an analysis of density of W. bancrofti
infection in the human (the community microfilarial load—
CMFL) and vector population. As a result our datasets will not be
particularly useful for mathematical disease modeling of the LF
transmission system, as determination of force of transmission is
difficult to approach using prevalence data alone.
The program met a number of challenges successfully. First was
the challenge of logistics. Plateau and Nasarawa states have a
combined population of over 4 million, comparable to that of a
small country. Distances to be traveled were great and many
villages were in very remote and difficult to access areas. Large
numbers of ivermectin and albendazole tablets shipped from two
different pharmaceutical companies at different times and entering
the country in different ways had to be coordinated to provide
both medicines to the same mouths at the same time. In the early
years, ivermectin for LF was ordered and imported differently
from ivermectin for onchocerciasis, meaning there were three drug
shipments for two drugs to be coordinated: albendazole shipments
for LF, ivermectin shipments for LF, and ivermectin shipments for
onchocerciasis (for the 12 LGAs that happened to be co-endemic
for LF). Another logistical problem was that of financing, ordering,
importing, and storing the ICT tests. ICTs were not available in
2001 and 2006 due to production shortages. The manufacturer
changed four times between 1998 and 2009, and with it the
required training for new card configurations. Prices increased
rather than decreased over the course of the program. The need to
refrigerate later versions of the tests meant considerable added
costs of purchasing refrigeration units, running generators (during
power outages), use of cold boxes to transfer tests to the field, etc.
Shortened shelf life of the tests to 3 months [11,13] made multiple
shipments in a year necessary. Logistics were also complicated by
the challenges of frequent government strikes by state and LGA
staff. The importance of having a focused NGO partner working
closely with the state and LGA MOHs helped overcome what
might have been insurmountable logistical and continuity issues.
Second was the challenge of insecurity, an ongoing concern in
Plateau and Nasarawa states. The presence of village-based local
resident distributors generally resulted in maintenance of treat-
ment coverage even when LMOH or SMOH teams had to restrict
their travel. For example in 2002 broad civil and religious unrest
challenged the program in 8 of the 30 LGAs (Bassa, Kanam,
Wase, Langtang North, Riyom, Doma, Keana, and Obi), but
treatments in those LGAs were not affected (data not shown). On
only one occasion, due to 2009 rioting in the city of Jos, Jos East
LGA (with its urban SV of Babale) could not be treated.
A new experience in 2003 was executing the MDA program in
urban environments. Up until then, program managers had only
worked in rural villages [35]. They learned very quickly that
treatment in urban areas could not rely on community volunteers
and traditional leadership structures. The new strategy was to
engage organized religious groups to mobilize community
participation and individual volunteerism: churches and mosques
were approached in neighborhoods where the preponderance of
the population was Christian or Moslem respectively. HE activities
were held largely on Fridays (Moslems) or Sundays (Christians).
Another urban innovation was the extensive use of TV and radio
LF ‘jingles,’ aired constantly in Hausa and English during the
campaign period. Rather than house to house, treatments were
organized in central locations that served as distribution posts,
commonly near a neighborhood church, mosque, health clinic or
hospital. Nurses in white uniforms or white coats were important
for these urban dwellers. While most treatment was still directly
observed, sometimes treatments had to be given to family
members to take home to absentees. Such practices were by and
large unheard of in rural MDA activities. The 2003 coverage
survey suggested that coverage in urban areas (61.9%, CI 56.6–
67.0) was less than overall coverage (72.2%, 95% CI 65.5–79.0),
but not significantly so.
From the onset, the program was committed to the concept of
developing an integrated model for NTD activities [26]. The LF
experience cannot be divorced from the longer standing
onchocerciasis efforts in Plateau and Nasarawa states. First there
was the important question of whether MDA for LF was even
necessary in the 12 LGAs where ivermectin monotherapy MDA
for onchocerciasis had been given for many years. Had there been
a ‘by-stander’ effect where onchocerciasis MDA had inadvertently
interrupted LF transmission? Our entomological, antigen and
patient studies concluded that (unfortunately) LF transmission and
morbidity persisted in such onchocerciasis monotherapy areas
[27,28,30]. Following that conclusion, we initiated the LF MDA
program by building upon the existing ivermectin delivery
platform, where both programs would use the same drug
(ivermectin) in the same LGAs. At the time, when integration
was not as fashionable as it is today, many LF experts criticized
launching the pilot LF program in an integrated fashion with
onchocerciasis, arguing that the first LF programs ought to be
launched in ivermectin naı ¨ve areas (our Phases 3 and 4) to enable
‘valid’ baseline (e.g., pretreatment) assessments of mf in SVs and
better ‘roll out’ monitoring of adverse events. Tension between the
LF program (seeking speed to reaching full geographic coverage
for LF elimination within six years) and the onchocerciasis
program (seeking 15–20 year sustainability of ivermectin distribu-
tion for onchocerciasis control) arose, particularly with respect to
selection and training of CDDs. The benefits of piggybacking the
LF program on the river blindness platform, however, were lost by
the third year of the program, as the LF program moved into the
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had to rapidly scale up new community distribution networks to
expand the MDA population under treatment by over 300%. By
the end of 2003, recruitment and training of CDDs increased by 3
fold compared to 2000, from 2,424 to 6,899. In attempts to
improve coverage and minimize workload further, the program
continued to increase CDD numbers annually, by training over
10,000 in 2009. Increased CDD numbers was associated with
improved village coverage, with the percentage of villages
achieving $85% coverage increasing from 50% in 2006 to 73%
in 2009.
As the LF program in Plateau and Nasarawa seeks to finance
and undertake additional assessments to determine when and
where MDA can be halted, considerations about the future of the
onchocerciasis control program will arise. Consider the two
options for MDA program adjustment within the 12 LF
onchocerciasis co-endemic LGAs if it is decided that LF
transmission has been broken: Option 1) Stop albendazole but
carry on with ivermectin MDA for onchocerciasis, while
conducting post treatment surveillance for LF recrudescence
(recrudescence would be less likely to occur in the presence of
ongoing ivermectin monotherapy compared to non onchocerciasis
endemic LGAs where both ivermectin and albendazole would be
stopped). Option 2) Determine the status of onchocerciasis
transmission, with the thought of stopping treatment for
onchocerciasis as well if indicated. Recent studies in parts of Mali
and Senegal have shown that onchocerciasis transmission has been
interrupted by 15 or more years of ivermectin treatment, and
MDA can be safely withdrawn [51]. If community wide MDA
treatments for LF and onchocerciasis can be stopped simulta-
neously in qualifying LGAs of Plateau and Nasarawa, then
surveillance teams can make the best of scarce resources by
undertaking ‘integrated’ post-treatment surveillance monitoring
for both conditions. In the interest of controlling soil transmitted
helminths (STH) and schistosomiasis, either scenario above would
potentially still require MDA with albendazole and/or praziquan-
tel in school aged children [52,53].
Managing these MDA transitions in Plateau and Nasarawa
states will be the final challenge. The complexity of modifying
programs will depend on the mosaic of epidemiological findings
likely to become more obvious in the near future as more
assessments are undertaken. Some LGAs (mostly likely those with
higher endemicity or poorer coverage) will require ‘mop up’ and
enhanced interventions and operations. Other LGAs might move
to post treatment surveillance activities. Individualized and
tailored programmatic processes must be resolved eventually by
the LGA level leadership and resources, where the health system
structures on ground need the greatest support.
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